Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 46

1.

A novel assay to assess primary human cancer infectibility by replication-selective oncolytic adenoviruses.

Wang Y, Thorne S, Hannock J, Francis J, Au T, Reid T, Lemoine N, Kirn D, Halldén G.

Clin Cancer Res. 2005 Jan 1;11(1):351-60.

PMID:
15671566
[PubMed - indexed for MEDLINE]
Free Article
2.

A novel ex vivo model system for evaluation of conditionally replicative adenoviruses therapeutic efficacy and toxicity.

Kirby TO, Rivera A, Rein D, Wang M, Ulasov I, Breidenbach M, Kataram M, Contreras JL, Krumdieck C, Yamamoto M, Rots MG, Haisma HJ, Alvarez RD, Mahasreshti PJ, Curiel DT.

Clin Cancer Res. 2004 Dec 15;10(24):8697-703.

PMID:
15623655
[PubMed - indexed for MEDLINE]
Free Article
3.

Evaluation of tissue-specific promoters in carcinomas of the cervix uteri.

Rein DT, Breidenbach M, Nettelbeck DM, Kawakami Y, Siegal GP, Huh WK, Wang M, Hemminki A, Bauerschmitz GJ, Yamamoto M, Adachi Y, Takayama K, Dall P, Curiel DT.

J Gene Med. 2004 Nov;6(11):1281-9.

PMID:
15368588
[PubMed - indexed for MEDLINE]
4.

Keloid fibroblast responsiveness to epidermal growth factor and activation of downstream intracellular signaling pathways.

Satish L, Babu M, Tran KT, Hebda PA, Wells A.

Wound Repair Regen. 2004 Mar-Apr;12(2):183-92.

PMID:
15086770
[PubMed - indexed for MEDLINE]
5.

Transcriptional targeting of adenoviral vector through the CXCR4 tumor-specific promoter.

Zhu ZB, Makhija SK, Lu B, Wang M, Kaliberova L, Liu B, Rivera AA, Nettelbeck DM, Mahasreshti PJ, Leath CA 3rd, Yamamoto M, Alvarez RD, Curiel DT.

Gene Ther. 2004 Apr;11(7):645-8. Erratum in: Gene Ther. 2006 Feb;13(4):374. Yamaoto, M [corrected to Yamamoto, M].

PMID:
15029227
[PubMed - indexed for MEDLINE]
6.

Transcriptional targeting of tumors with a novel tumor-specific survivin promoter.

Zhu ZB, Makhija SK, Lu B, Wang M, Kaliberova L, Liu B, Rivera AA, Nettelbeck DM, Mahasreshti PJ, Leath CA, Barker S, Yamaoto M, Li F, Alvarez RD, Curiel DT.

Cancer Gene Ther. 2004 Apr;11(4):256-62.

PMID:
15017380
[PubMed - indexed for MEDLINE]
7.

A cyclooxygenase-2 promoter-based conditionally replicating adenovirus with enhanced infectivity for treatment of ovarian adenocarcinoma.

Kanerva A, Bauerschmitz GJ, Yamamoto M, Lam JT, Alvarez RD, Siegal GP, Curiel DT, Hemminki A.

Gene Ther. 2004 Mar;11(6):552-9.

PMID:
14999227
[PubMed - indexed for MEDLINE]
8.

The effect of sequestration by nontarget tissues on anti-tumor efficacy of systemically applied, conditionally replicating adenovirus vectors.

Bernt KM, Ni S, Gaggar A, Li ZY, Shayakhmetov DM, Lieber A.

Mol Ther. 2003 Nov;8(5):746-55. Erratum in: Mol Ther. 2004 Jan;9(1):139.

PMID:
14599807
[PubMed - indexed for MEDLINE]
9.

Infectivity enhanced, cyclooxygenase-2 promoter-based conditionally replicative adenovirus for pancreatic cancer.

Yamamoto M, Davydova J, Wang M, Siegal GP, Krasnykh V, Vickers SM, Curiel DT.

Gastroenterology. 2003 Oct;125(4):1203-18.

PMID:
14517802
[PubMed - indexed for MEDLINE]
10.

Virotherapeutics: conditionally replicative adenoviruses for viral oncolysis.

Nettelbeck DM.

Anticancer Drugs. 2003 Sep;14(8):577-84. Review.

PMID:
14501378
[PubMed - indexed for MEDLINE]
11.

Assessment of hepatocytes and liver slices as in vitro test systems to predict in vivo gene expression.

Jessen BA, Mullins JS, De Peyster A, Stevens GJ.

Toxicol Sci. 2003 Sep;75(1):208-22. Epub 2003 Jun 27.

PMID:
12832660
[PubMed - indexed for MEDLINE]
Free Article
12.

Cyclooxygenase-2 promoter for tumour-specific targeting of adenoviral vectors to melanoma.

Nettelbeck DM, Rivera AA, Davydova J, Dieckmann D, Yamamoto M, Curiel DT.

Melanoma Res. 2003 Jun;13(3):287-92.

PMID:
12777984
[PubMed - indexed for MEDLINE]
13.

Survivin gene expression positively correlates with proliferative activity of cancer cells in esophageal cancer.

Ikeguchi M, Yamaguchi K, Kaibara N.

Tumour Biol. 2003 Jan-Feb;24(1):40-5.

PMID:
12743425
[PubMed - indexed for MEDLINE]
14.

Expression of the inhibitor of apoptosis protein survivin in benign meningiomas.

Das A, Tan WL, Smith DR.

Cancer Lett. 2003 Apr 25;193(2):217-23.

PMID:
12706880
[PubMed - indexed for MEDLINE]
15.

The secretory leukoprotease inhibitor (SLPI) promoter for ovarian cancer gene therapy.

Barker SD, Coolidge CJ, Kanerva A, Hakkarainen T, Yamamoto M, Liu B, Rivera AA, Bhoola SM, Barnes MN, Alvarez RD, Curiel DT, Hemminki A.

J Gene Med. 2003 Apr;5(4):300-10.

PMID:
12692864
[PubMed - indexed for MEDLINE]
16.

Expression of the anti-apoptotic gene survivin correlates with taxol resistance in human ovarian cancer.

Zaffaroni N, Pennati M, Colella G, Perego P, Supino R, Gatti L, Pilotti S, Zunino F, Daidone MG.

Cell Mol Life Sci. 2002 Aug;59(8):1406-12.

PMID:
12363043
[PubMed - indexed for MEDLINE]
17.

The role of chemokines in melanoma tumor growth and metastasis.

Payne AS, Cornelius LA.

J Invest Dermatol. 2002 Jun;118(6):915-22. Review.

PMID:
12060384
[PubMed - indexed for MEDLINE]
Free Article
18.

Expression of survivin, a novel inhibitor of apoptosis and cell cycle regulatory protein, in pancreatic adenocarcinoma.

Sarela AI, Verbeke CS, Ramsdale J, Davies CL, Markham AF, Guillou PJ.

Br J Cancer. 2002 Mar 18;86(6):886-92.

PMID:
11953819
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Recent trends in breast cancer incidence and mortality.

Lacey JV Jr, Devesa SS, Brinton LA.

Environ Mol Mutagen. 2002;39(2-3):82-8. Review.

PMID:
11921173
[PubMed - indexed for MEDLINE]
20.

Midkine promoter-based adenoviral suicide gene therapy to midkine-positive pediatric tumor.

Adachi Y, Matsubara S, Muramatsu T, Curiel DT, Reynolds PN.

J Pediatr Surg. 2002 Apr;37(4):588-92.

PMID:
11912516
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk